Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

ForkLibertarian · 2026-04-06T18:24:54+00:00

Viridian Therapeutics' shares dropped 21% after Amgen announced successful results for its eye treatment Tepezza, which had a 77% response rate, contrasting with Viridian's 51% response for its Elegrobart treatment.

ForkLibertarian

2026-04-06 18:24:54

Abstract generation in progress

By Katherine Hamilton

Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza.

The stock fell 21% to $14.73, extending some declines seen since reporting its own eye-treatment results March 30. Shares have fallen by more than 50% year to date.

Amgen’s Tepezza showed a 77% response rate in patients partaking in a 24-week Phase 3 study.

The results come after Viridian posted results for its own thyroid eye treatment, Elegrobart, reporting a 51% overall responder rate among patients who were treated, versus 16% among the placebo group.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 06, 2026 13:09 ET (17:09 GMT)

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes